Ann: Proposed Acquisition of ResApp Health by Pfizer, page-396

The reality is that RAP needs an event that will move the share price higher than 11.5 cents ahead of the June vote. Whether that be a bid from another suitor or amazing Q1 revenue or possibly some other ace in the hole from the board? Then a much, much better offer is ultimately possible.

Pfizer is a USD311 billion MC company so they can and will pay more if they are forced to. They clearly want this technology.

Otherwise, we go in around 11.5c and presuming the offer gets rejected, Pfizer’s analysts will have already crunched the numbers on what a subsequent takeover offer would need to look like based on the percentage that vote yes - almost certainly though it would be only somewhere in the teens.